WILLIAM WONG to Liver Neoplasms
This is a "connection" page, showing publications WILLIAM WONG has written about Liver Neoplasms.
Connection Strength
2.138
-
Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario. Pharmacoeconomics. 2023 04; 41(4):413-425.
Score: 0.382
-
Feasibility of hepatitis B elimination in high-income countries with ongoing immigration. J Hepatol. 2022 10; 77(4):947-956.
Score: 0.363
-
Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study. CMAJ Open. 2021 Jan-Mar; 9(1):E167-E174.
Score: 0.335
-
Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis. J Viral Hepat. 2021 02; 28(2):260-267.
Score: 0.328
-
Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis. Oncologist. 2020 03; 25(3):e512-e519.
Score: 0.306
-
Disease burden of chronic hepatitis B among immigrants in Canada. Can J Gastroenterol. 2013 Mar; 27(3):137-47.
Score: 0.192
-
Impact of new direct-acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection. Liver Int. 2024 Jun; 44(6):1383-1395.
Score: 0.103
-
Cost Effectiveness of Hepatocellular Carcinoma Surveillance?After a Sustained Virologic Response to Therapy?in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1840-1849.e16.
Score: 0.072
-
Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. Breast Cancer Res Treat. 2015 Jun; 151(3):639-52.
Score: 0.056